BTK and mantle cell lymphoma: In this study we have developed the most potent to date BRD4/PI3K/BTK inhibitor, SRX3305, that shows enhanced preclinical efficacy in MCL cells and overcomes Ibrutinib resistance by inducing cytotoxic mediated cell death in the acquired Ibrutinib resistance cells.